Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer
Xintong Li, Ze Zhang, Fangyan Gao, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 16, pp. 9334-9342
Closed Access | Times Cited: 64

Showing 26-50 of 64 citing articles:

(GGAA)3-Based TF-PROTACs Enable Targeted Degradation of ETV6 to Inhibit Ewing Sarcoma Growth
Zhichuan Zhu, He Chen, Xing Qiu, et al.
Journal of the American Chemical Society (2025)
Closed Access
Defeating MYC with drug combinations or dual-targeting drugs
Philip E. Thompson, Jake Shortt
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 490-502
Closed Access | Times Cited: 4
High-content tailoring strategy to improve the multifunctionality of functional nucleic acids
Keren Chen, Longjiao Zhu, Jie Li, et al.
Biosensors and Bioelectronics (2024) Vol. 261, pp. 116494-116494
Closed Access | Times Cited: 4
Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers
Aishwarya Saraswat, Hari Priya Vemana, Vikas V. Dukhande, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102292-102292
Open Access | Times Cited: 4
Selection of biofilm-inhibiting ssDNA aptamers against antibiotic-resistant Edwardsiella tarda by inhibition-SELEX and interaction with their binding proteins
Yunting Fan, Jiang Zheng, Ying Tan, et al.
International Journal of Biological Macromolecules (2025), pp. 140041-140041
Closed Access
Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma
Annika Gustafson, Adam D. Durbin, Kristin Artinger, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
PROTACs coupled with oligonucleotides to tackle the undruggable
Guangshuai Zhang, Si Yan, Yan Liu, et al.
Bioanalysis (2025), pp. 1-16
Closed Access
Chemical evolution of ASO-like DNAzymes for effective and extended gene silencing in cells
Yingyu Liu, Sheyu Zhang, Meiqi Zhang, et al.
Nucleic Acids Research (2025) Vol. 53, Iss. 5
Open Access
Biotoxins and Their Conjugates for Use in Targeted Medicinal Applications with Focus on Eye Diseases
P Arumugam, Sukanya Sukanya, Sumit Mohan, et al.
(2025), pp. 303-333
Closed Access
Berberine restrained proliferation, invasion, and migration by targeting the glycogen synthase kinase 3β/β-catenin pathway in lung adenocarcinoma cells
Tenzin Wangmu, Chenlu Li, Guangsu Han, et al.
Oncology and Translational Medicine (2025) Vol. 11, Iss. 2, pp. 58-72
Open Access
Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
Mohammad Hajimolaali, Farid Abedin Dorkoosh, Sophia G. Antimisiaris
Journal of Liposome Research (2024) Vol. 34, Iss. 4, pp. 671-696
Closed Access | Times Cited: 3
Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy
Jianfei Xu, Xiaoran Zhao, Xingxing Liang, et al.
Science Advances (2024) Vol. 10, Iss. 38
Open Access | Times Cited: 3
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
Yerim Jin, Yeongju Lee
ChemMedChem (2024) Vol. 19, Iss. 23
Open Access | Times Cited: 2
G‐quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy
Ruixi Peng, Qian Huang, Li Wang, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 47
Closed Access | Times Cited: 2
BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression
Yanjie Kong, Tianlong Lan, Luzhen Wang, et al.
Oncogene (2024) Vol. 43, Iss. 39, pp. 2914-2926
Open Access | Times Cited: 2
Targeting Oncogenic Transcriptional Factor c-Myc by Oligonucleotide PROTAC for the Treatment of Hepatocellular Carcinoma
Min Ai, Hulin Ma, Jianhua He, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116978-116978
Closed Access | Times Cited: 2
Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities
Harshita Tiwari, Swati Singh, Sonal Sharma, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 2
Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research
Mariona Pont, Marta Marqués, Anabel Sorolla
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13518-13518
Open Access | Times Cited: 2
Functional nucleic acids with synthetic sugar or nucleobase moieties
Ze Zhang, Siqi Chen, Zhe Li, et al.
Advanced Agrochem (2023) Vol. 2, Iss. 3, pp. 236-245
Open Access | Times Cited: 6
Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor
Miyako Naganuma, Nobumichi Ohoka, Genichiro Tsuji, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 10, pp. 1780-1788
Closed Access | Times Cited: 5
A cocktail therapeutic strategy based on clofarabine-containing aptamer-PROTAC for enhanced cancer therapy
Zhenzhen Chen, Mohan Chen, Ran Liu, et al.
Chemical Communications (2023) Vol. 59, Iss. 77, pp. 11560-11563
Closed Access | Times Cited: 4
Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2
Zhen Wang, Jing Liu, Xing Qiu, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 40, pp. 21871-21878
Open Access | Times Cited: 4
PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives
Makenzie Vorderbruggen, Carlos A. Velázquez‐Martínez, Amarnath Natarajan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5067-5067
Open Access | Times Cited: 1
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed
Karim Kanbar, Roy El Darzi, Diana E. Jaalouk
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 1
Developing MYC Degraders Bearing the Von Hippel–Lindau Ligand to Target the “Undruggable” MYC
Christos Siokatas, Άννα Λαμπροπούλου, Alexandra Smina, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3955-3968
Open Access | Times Cited: 1

Scroll to top